Answers are grounded in this paper and cite their sources.
Oral semaglutide was non-inferior to subcutaneous semaglutide and superior to placebo and another GLP-1 RA in reducing HbA1c and body weight. It was superior to subcutaneous semaglutide and inferior to other GLP-1 RA comparators and placebo in terms of the incidence of adverse events. Thus, oral semaglutide provides a convenient administration route for patients who prefer oral treatments over injectable therapies.
No takes yet. Share an insight, caveat, or question.
Alhindi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: